We speculate that targeted inhibition of heme-mediated TLR4 signaling would be beneficial in hemolytic diseases such as SCD without affecting innate immunity to gram negative bacteria expressing LPS. This evidence concerns the gene TLR4 and Schnyder corneal dystrophy.